Expert Discusses Durable Results With Nivolumab/Ipilimumab in mCRC, Future of Immunotherapy – Targeted Oncology
Targeted Oncology |
Expert Discusses Durable Results With Nivolumab/Ipilimumab in mCRC, Future of Immunotherapy
Targeted Oncology In the first report of the full cohort of 119 patients in the CheckMate-142 study, positive results were demonstrated with nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) in patients with previously treated microsatellite … |
